These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12945474)

  • 1. An analysis of first authorizations for lipid-lowering drugs in Belgium.
    Devroey D; Betz W
    Acta Clin Belg; 2003; 58(3):152-8. PubMed ID: 12945474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The results of dietary advice on lipoprotein levels among patients attending for lipid-lowering drugs.
    Devroey D; Betz W
    Cent Eur J Public Health; 2004 Sep; 12(3):131-3. PubMed ID: 15508411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of reimbursement criteria on the appropriateness of 'statin' prescribing.
    Autier P; Creplet J; Vansant G; Brohet C; Paquot N; Muls E; Mullie P; Grivegnée AR
    Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):456-62. PubMed ID: 14671469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey.
    Sukonthasarn A; Homsanit M; Prommete B; Chotinaiwattarakul C; Piamsomboon C; Likittanasombat K
    J Med Assoc Thai; 2011 Dec; 94(12):1424-34. PubMed ID: 22295727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [On the inapplicability of certain therapeutic guidelines in practice: the example of reimbursement for hypolipidemic agents in Belgium].
    Scheen AJ
    Rev Med Liege; 2000 Apr; 55(4):260-4. PubMed ID: 10909311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of pharmaceutical treatment of dyslipidaemia among patients without diagnosed atherosclerotic disease in Belgium.
    Devroey D; Betz W; Kartounian J
    Int J Clin Pract; 2003 Oct; 57(8):720-5. PubMed ID: 14627185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adequacy of the pharmacologic treatment to the recommendations of a performance protocol in hypercholesterolemia in primary care].
    Martínez G; Quiñones S; Castillo L; Ramos A; Avellana E; Ciurana R; Mata M
    Aten Primaria; 1996 Sep; 18(4):176-81. PubMed ID: 8962997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia.
    Matsuo T; Iwade K; Hirata N; Yamashita M; Ikegami H; Tanaka N; Aosaki M; Kasanuki H
    Heart Vessels; 2005 Feb; 20(1):8-12. PubMed ID: 15700196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
    Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
    Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.